AI will inevitably bring revolutionary benefits to pharma, but the transformation will be more gradual and nuanced than in other industries, writes Bristol Myers Squibb’s chief digital and technology officer.
Why isn’t AI transforming biopharma as fast as we’d like?
This was originally published on post